Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties

Pavot, Vincent; Rochereau, Nicolas; Primard, Charlotte; Genin, Christian; Pérouzel, Éric; Lioux, Thierry; Paul, Stéphane; Verrier, Bernard

doi:10.1016/j.jconrel.2013.01.015

Cited by 79 publications

(75 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poly(lactic acid) (PLA) NPs (180 nm) were prepared by nanoprecipitation, as previously described (16), and provided by Adjuvatis (Lyon, France). P24 protein and PLA particles were diluted in PBS at 200 mg/ml and 5 mg/ml, respectively.…”

Section: Methodsmentioning

confidence: 99%

Cutting Edge: New Chimeric NOD2/TLR2 Adjuvant Drastically Increases Vaccine Immunogenicity

Pavot

Rochereau

Rességuier

et al. 2014

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

TLR ligands are critical activators of innate immunity and are being developed as vaccine adjuvants. However, their usefulness in conjunction with NOD-like receptor agonists remains poorly studied. In this study, we evaluated a new ligand that targets both TLR2 and NOD2 receptors. We assessed its ability to enhance dendritic cell maturation in vitro in addition to improving systemic and mucosal immune responses in mice. The chimeric NOD2/TLR2 ligand induced synergistic upregulation of dendritic cell maturation markers, costimulatory molecules, and secretion of proinflammatory cytokines compared with combinations of separate ligands. Furthermore, when coadministered with biodegradable nanoparticles carrying a model Ag, the ligand was able to induce high Ag-specific IgA and IgG titers at both systemic and mucosal sites after parenteral immunizations. These findings point out the potential utility of chimeric molecules TLR/NOD as adjuvants for vaccines to induce systemic and mucosal immune responses.

show abstract

Section: Methodsmentioning

confidence: 99%

Cutting Edge: New Chimeric NOD2/TLR2 Adjuvant Drastically Increases Vaccine Immunogenicity

Pavot

Rochereau

Rességuier

et al. 2014

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The authors used poly (lactic acid) nanoparticles carrying Gag p24 HIV-1 antigen to encapsulate NOD ligands and efficiently target DCs. The coinjection of encapsulated NOD ligands with the antigen resulted in a mark increased antibody response compared with the common adjuvant alum (79).…”

Section: Adjuvant Combinationsmentioning

confidence: 99%

Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants

Maisonneuve

Bertholet

Philpott

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

261

203

View full text Add to dashboard Cite

Innate immunity confers an immediate nonspecific mechanism of microbial recognition through germ line-encoded pattern recognition receptors (PRRs). Of these, Toll-like receptors (TLRs) and nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) have shaped our current understanding of innate regulation of adaptive immunity. It is now recognized that PRRs are paramount in instructing an appropriate adaptive immune response. Their ligands have been the focus of adjuvant research with the goal of generating modern vaccine combinations tailored to specific pathogens. In this review we will highlight the recent findings in the field of adjuvant research with a particular focus on the potential of TLR and NLR ligands as adjuvants and their influence on adaptive immune responses.

show abstract

“…Cruz et al demonstrated that targeting the DC-SIGN improved antigen processing by human DCs and thus resulted in increased antigen-specific T-cell activation with reduced antigen concentrations 10 to 100-fold. 107 Similarly, several TLR and NOD ligands have been incorporated into PLGA nanoparticles, such as TLR-4 ligand (7-acyl lipid A), 108 TLR-9 ligand (CpG), 109 and NOD 1 and NOD 2 ligands (CL235 and CL365, respectively) 110 which enhances the immunogenicity of particle-based vaccines by increasing APC activation.…”

Section: Specific Targeting Of Skin Apcsmentioning

confidence: 99%